Teal Health has developed the Teal Wand, the first FDA-authorised at-home cervical cancer screening device in the United States. The soft-sponge vaginal self-collection device allows women to collect samples at home and mail them to a lab, where they are processed using the same Roche cobas HPV test used in clinical settings, with 95% accuracy. Co-founded in 2020 by Kara Egan and Dr Avnesh Thakor, Teal Health addresses a critical gap: whilst cervical cancer is nearly 100% preventable, roughly 13,000 American women will be diagnosed this year because one in three are not up to date on screening. Almost half of Teal's users were behind on screening, and nearly 20% had never been screened despite being within screening age. The company spent four years developing the device with IDEO, focusing on patient experience rather than clinical efficiency.

Teal Health secured FDA marketing authorization in May 2025 for its breakthrough device addressing a critical gap in women's health care, specifically cervical cancer screening. The device received FDA Breakthrough Device designation due to its public health importance, as one in four women are behind on screenings. This achievement helped Teal Health raise $23 million in funding.

Teal Health's at-home cervical cancer screening test, the Teal Wand, received FDA approval. The device, resembling a tampon, matches the accuracy of traditional tests and is covered by major insurers. Teal Health raised $23 million from Serena Ventures, Metrodora, and Labcorp. The test addresses access, convenience, and discomfort issues, encouraging more women to stay current with screenings. In trials, 94% preferred it over in-office tests, and 86% would screen more regularly at home.